SUPRIYA LIFESCIENCE LIMITED (SUPRIYA): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹631.25 latest close · −35.5% over the last 90 sessions

₹631.25 month-end · −15.6% over 12 months

₹631.25 month-end · +116.7% over 3 years

₹631.25 month-end · +30.5% since Dec '21

52-week range ₹545.50 to ₹1085.00 · 1-year volatility 53.2%

Was the rally earned?

1 year3 years

-16%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

Per-share earnings added 10 points, but investors now pay less per rupee of profit (P/E 33.8x to 25.6x), which took 25 points back.
The share count barely moved.

Net profit growth+10 ptsNet profit rose about 11%, which lifts the price.

P/E change-25 ptsThe P/E fell from 33.8x to 25.6x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

+117%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

Per-share earnings added 119 points, but investors now pay less per rupee of profit (P/E 26.1x to 25.6x), which took 3 points back.
The share count barely moved.

Net profit growth+119 ptsNet profit rose about 120%, which lifts the price.

P/E change-3 ptsThe P/E fell from 26.1x to 25.6x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-69.1%recovered 2024-09

1-year volatility53.2%annualised

Beta vs sector index1.353-year daily, correlation 0.40

Volume spikes5last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-69.1% (2022-01 peak to 2023-03 low, recovered 2024-09)

-40.0% (2026-06 peak to 2026-11 low, not yet recovered)

-31.4% (2024-11 peak to 2026-03 low, recovered 2026-05)

Most recent volume spikes

2026-11-09: 15.7x the 50-day median, price -3.0% that day

2026-11-06: 10.2x the 50-day median, price -20.0% that day

2026-09-07: 5.2x the 50-day median, price +6.6% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

25.6xP/E todayWithin its usual range

Against its own history37th percentile

CheapestMedian 28.5xDearest

Usual range 13.1x to 36.9x since 2021-12.

Against Health Technology25.6x vs 37.0x

This company

25.6x

Sector median

37.0x

31% below the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE82nd▼ 5 pts vs a year ago
Op. margin77th▼ 21 pts vs a year ago
Revenue growth80th▲ 11 pts vs a year ago
EPS growth55th▼ 21 pts vs a year ago
Debt/equity ↓95thflat vs a year ago
Cash cycle ↓45th▼ 3 pts vs a year ago
P/E ↓70th▲ 22 pts vs a year ago
12M momentum22nd▼ 42 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~21%annual earnings growth implied by the priceBelow delivered growth

At normalised P/E (five-year average earnings) of 33.4x, a holder earning 12%/yr needs earnings to grow about 21.1%/yr for 10 years, then trade at 15x.

Delivered36.8%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg

Gap−15.7 ptsimplied minus delivered

Rank757thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	22.7%	23.8%	24.9%
15x	20.0%	21.1%	22.2%
20x	16.7%	17.7%	18.8%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 21.1%/yr

Looking back

Jan 2022Price implied 19%/yr; EPS has since grown 10%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹631.25
P/E: 25.6x
ROCE: 25.0%
Market Cap: ₹5082 cr
Revenue (TTM): ₹873 cr
P/S: 5.8x
P/B: 4.2x
ROE: 16.6%
Operating Margin: 25.0%
Debt / Equity: 0.0x
Promoter Holding: 68.3%
12M Momentum: -15.6%

52-week range

₹545.50₹1085.00

16% of the way from its 52-week low to its high

Price risk

1Y volatility

53.2%

Beta vs sector

1-year daily

1.06

Balance sheet & cash

Debt service

no meaningful debt

Cash from profit, 3Y

operating cash flow ÷ net profit

0.90x

Share count, 1Y

unchanged

Are profits backed by cash?

4 of 7checks within range3 near a threshold

Other income reliance4%Within range

Other income as a share of pre-tax profit (trailing twelve months): 4.1%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.90xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.90x (cash from operations ₹464 cr, net profit ₹516 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+27 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 27 days (97 vs 70). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress5% of fixed assetsWithin range

Capital work-in-progress is 5% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+61 days / 2 yrsNear threshold

Days payable changed by +61 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, DIIs trimmed 1.9 pts; FIIs added 0.8 pts.
The number of shareholders fell from 92,991 to 82,082 (-12%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters68.3%68.3%0.0 pts

FIIs5.3%6.2%+0.8 pts

DIIs7.2%5.3%-1.9 pts

Public and others19.2%20.2%+1.0 pts

Number of shareholders

82,082shareholders-12% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−15.2%typical 12-month return vs the marketBelow the base rate

We found 50 past situations where a non-financial company looked like SUPRIYA LIFESCIENCE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −30% to +7% vs the market, against −7% for all non-financial companies in the same months.
The analogs' median sat below that base rate (gap −8.4%, 80% range −16.8% to −4.0%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median

−15.2%

All companies' median

−6.8%

Beat the market

34% vs 43%

50 past situations · 50 companies · 34 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
VOLTAMP Producer Manufacturing	Jun 2025	30x	29%	−14%	−34%	+9%
ADVENZYMES Consumer Non-Durables	Jul 2021	31x	22%	+110%	−18%	−33%
JUSTDIAL Technology Services	Mar 2020	9x	22%	−51%	−64%	+64%
FCL Process Industries	Aug 2023	39x	36%	+14%	−20%	−20%
AURIONPRO Technology Services	Sep 2025	32x	18%	−30%	−39%	−46%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ELECON Producer Manufacturing	Feb 2025	26x	31%	−17%	−43%	−15%
CONCORDBIO Health Technology	Oct 2025	21x	28%	−21%	−38%	−9%
NUCLEUS Technology Services	Mar 2024	25x	27%	+85%	−32%	−35%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, P/E and size. Not used (unavailable for this company): interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SUPRIYA LIFESCIENCE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

GOLDIAM INTERNATIONALGOLDIAM

Consumer Durables

75%similar

market capROCE

ANTELOPUS SELAN ENERGYANTELOPUS

Energy Minerals

72%similar

debt/equityP/E

MPSMPSLTD

Consumer Services

67%similar

promoter holdingrevenue

INDO TECH TRANSFORMERSINDOTECH

Producer Manufacturing

66%similar

revenuedebt/equity

INFOBEANS TECHNOLOGIESINFOBEAN

Technology Services

64%similar

EPS growthROCE

RPG LIFE SCIENCESRPGLIFE

Health Technology

60%similar

ROCEmarket cap

SYNCOM FORMULATIONS (INDIA) LTSYNCOMF

Health Technology

59%similar

ROCEdebt/equity

NGL FINE CHEMNGLFINE

Health Technology

48%similar

revenue growthvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Dec '22

2026
NovPriceFell 40% from the Jun 2026 peak to the Nov 2026 low.
NovPriceVolume reached 15.7x its 50-day median on 2026-11-09; price -3.0% that day.
SepValuationP/E crossed above the 90th percentile of its own history to date (38.5x).
JulPriceVolume reached 9.4x its 50-day median on 2026-07-06; price -11.6% that day.
MayPriceRegained the 2024-11 peak, 2 months after the low.
MayValuationP/E crossed above the 90th percentile of its own history to date (42.1x).
MayPriceVolume reached 34.7x its 50-day median on 2026-05-29; price +20.0% that day.
MarPriceFell 31% from the Nov 2024 peak to the Mar 2026 low.

Show 22 earlier events

2025
DecResultsRevenue (TTM) reached a new high of ₹715 cr.
DecPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
OctPriceVolume reached 7.4x its 50-day median on 2025-10-31; price +3.4% that day.
SepPriceVolume reached 12.2x its 50-day median on 2025-09-19; price +5.4% that day.
JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
2024
DecPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
NovPriceVolume reached 18.7x its 50-day median on 2024-11-22; price +14.7% that day.
SepPriceRegained the 2022-01 peak, 18 months after the low.
AugValuationP/E crossed above the 90th percentile of its own history to date (36.9x).
AugPriceVolume reached 31.6x its 50-day median on 2024-08-12; price +13.9% that day.
JunResultsYear-on-year EPS growth turned positive.
JunPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
FebPriceVolume reached 23.7x its 50-day median on 2024-02-08; price +13.0% that day.
2023
DecValuationP/E crossed above the 90th percentile of its own history to date (28.2x).
NovPriceVolume reached 14.2x its 50-day median on 2023-11-24; price +10.7% that day.
JulPriceVolume reached 11.5x its 50-day median on 2023-07-27; price +8.2% that day.
JunResultsYear-on-year EPS growth turned negative.
JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
MayPriceVolume reached 36.9x its 50-day median on 2023-05-12; price +11.4% that day.
MarPriceFell 69% from the Jan 2022 peak to the Mar 2023 low.
FebPriceVolume reached 16.2x its 50-day median on 2023-02-17; price +8.4% that day.
2022
DecSharesShare count is up 6.7% over 12 months.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	25.6x	₹873 cr	16.6%	25.0%	0.0x
2026-10	34.4x	₹873 cr	16.5%	25.0%	0.0x
2026-09	38.5x	₹873 cr	16.5%	25.0%	0.0x
2026-08	30.7x	₹828 cr	17.4%	25.0%	0.0x
2026-07	33.4x	₹828 cr	17.4%	25.0%	0.0x
2026-06	39.2x	₹828 cr	17.4%	25.0%	0.0x
2026-05	42.1x	₹735 cr	18.6%	27.0%	0.0x
2026-04	30.2x	₹735 cr	18.6%	27.0%	0.0x
2026-03	24.4x	₹735 cr	18.6%	27.0%	0.0x
2026-02	28.9x	₹715 cr	18.3%	27.0%	0.0x
2026-01	29.8x	₹715 cr	18.3%	27.0%	0.0x
2025-12	33.2x	₹715 cr	18.3%	27.0%	0.0x
2025-11	33.8x	₹681 cr	17.9%	27.0%	0.0x
2025-10	35.1x	₹681 cr	17.9%	27.0%	0.0x
2025-09	33.0x	₹681 cr	17.9%	27.0%	0.0x
2025-08	28.0x	₹697 cr	18.9%	27.0%	0.0x
2025-07	28.3x	₹697 cr	18.9%	27.0%	0.0x
2025-06	30.4x	₹697 cr	18.9%	27.0%	0.0x
2025-05	33.4x	₹671 cr	21.5%	22.0%	0.0x
2025-04	29.8x	₹671 cr	21.5%	22.0%	0.0x
2025-03	33.9x	₹671 cr	21.5%	22.0%	0.0x
2025-02	30.5x	₹625 cr	19.4%	22.0%	0.0x
2025-01	36.8x	₹625 cr	19.4%	22.0%	0.0x
2024-12	37.8x	₹625 cr	19.4%	22.0%	0.0x
2024-11	46.2x	₹599 cr	16.7%	22.0%	0.0x
2024-10	37.1x	₹599 cr	16.7%	22.0%	0.0x
2024-09	33.5x	₹599 cr	16.7%	22.0%	0.0x
2024-08	36.9x	₹570 cr	14.7%	22.0%	0.0x
2024-07	26.9x	₹570 cr	14.7%	22.0%	0.0x
2024-06	26.2x	₹570 cr	14.7%	22.0%	0.0x
2024-05	32.9x	₹461 cr	12.9%	19.0%	0.0x
2024-04	35.5x	₹461 cr	12.9%	19.0%	0.0x
2024-03	29.8x	₹461 cr	12.9%	19.0%	0.0x
2024-02	30.8x	₹461 cr	12.9%	19.0%	0.0x
2024-01	27.3x	₹461 cr	12.9%	19.0%	0.0x
2023-12	28.2x	₹461 cr	12.9%	19.0%	0.0x
2023-11	26.1x	₹461 cr	12.9%	19.0%	0.0x
2023-10	22.4x	₹461 cr	12.9%	19.0%	0.0x
2023-09	25.1x	₹461 cr	12.9%	19.0%	0.0x
2023-08	25.1x	₹461 cr	12.9%	19.0%	0.0x
2023-07	22.9x	₹461 cr	12.9%	19.0%	0.0x
2023-06	22.2x	₹461 cr	12.9%	19.0%	0.0x
2023-05	13.2x	₹530 cr	24.7%	43.0%	0.0x
2023-04	11.5x	₹530 cr	24.7%	43.0%	0.0x
2023-03	10.1x	₹530 cr	24.7%	43.0%	0.0x
2023-02	10.5x	₹530 cr	24.7%	43.0%	0.0x
2023-01	11.4x	₹530 cr	24.7%	43.0%	0.0x
2022-12	12.5x	₹530 cr	24.7%	43.0%	0.0x
2022-11	13.0x	₹530 cr	24.7%	43.0%	0.0x
2022-10	15.2x	₹530 cr	24.7%	43.0%	0.0x
2022-09	15.9x	₹530 cr	24.7%	43.0%	0.0x
2022-08	18.8x	₹530 cr	24.7%	43.0%	0.0x
2022-07	20.0x	₹530 cr	24.7%	43.0%	0.0x
2022-06	19.0x	₹530 cr	24.7%	43.0%	0.0x
2022-05	21.1x	₹391 cr	46.1%	60.0%	0.3x
2022-04	24.8x	₹391 cr	46.1%	60.0%	0.3x
2022-03	29.2x	₹391 cr	46.1%	60.0%	0.3x
2022-02	24.9x	₹391 cr	46.1%	60.0%	0.3x
2022-01	27.4x	₹391 cr	46.1%	60.0%	0.3x
2021-12	28.6x	₹391 cr	46.1%	60.0%	0.3x

Methodology and data notes